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SUMMARY 
Data from large international clinical trials conducted in the past 5 years have rapidly improved 
the treatment of chronic hepatitis C; however, it is unclear whether the advances seen in clinical 
trials are being paralleled by similar improvements in treatment outcomes obtained during routine 
clinical practice. We have conducted an observational study of 219 patients receiving pegylated 
interferon alfa-2b (1.5 µg/kg/wk) and weight-based ribavirin (800-1200 mg/day) for 48 weeks. 
The primary study end point was sustained virological response (SVR), defined as undetectable 
HCV RNA 6 months after the completion of treatment. In total, 108 patients (49.3 %) had 
undetectable HCV RNA at the end of therapy, and 91 (41.6%) attained SVR at the end of follow-
up. Of the 111 patients who did not attain an end-of-treatment response, 28 were non-responders 
with continuously detectable HCV RNA during the 48-week treatment period, and 21 had 
virological breakthrough. In total, 134 patients attained early virological response (EVR); 88 of 
those patients attained SVR. In contrast, 82 of the 85 patients who did not attain EVR also did not 
attain SVR. Age, fibrosis score, and baseline viral load were identified as important predictors of 
treatment outcome. The most frequently reported serious adverse events resulting in treatment 
discontinuation were anemia (n = 10), fatigue/asthenia/malaise (n = 6) and fever (n = 3). Our data 
indicate that treatment of chronic hepatitis C with PEG-IFN alfa-2b plus weight-based ribavirin 
results in favorable treatment outcomes in a community-based clinical practice in a Belgian 
cohort. 
Keywords: community-based, hepatitis C virus, pegylated interferon alfa-2b, ribavirin, 
tolerability, treatment  
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INTRODUCTION 
Hepatitis C virus (HCV) infection is a major global health problem. Worldwide approximately 
170 million persons are infected with HCV; the overall prevalence is 3% to 5% [1]. Because this 
infection frequently leads to progressive liver disease, cirrhosis, and hepatocellular carcinoma, 
hepatitis C is thought to be responsible for at least 20% of all deaths from chronic liver disease, 
amounting to 280,000 fatalities worldwide each year [2]. 
 
Hepatitis C is a significant healthcare concern in Belgium. During the early 1990s, the 
seroprevalence was estimated at 0.9% [3]; however, 10 years later, a second survey based on the 
presence of hepatitis C antibodies in oral fluid reported an overall prevalence of 0.12% [4]. The 
profile of hepatitis C in Belgium is typical of many other European and Western countries in 
terms of risk factors and genotype distribution. Transfusion, intravenous drug use, and invasive 
medical procedures are responsible for most infections [5]. Genotype 1, the most common HCV 
type, is responsible for approximately 60% of all infections. Genotypes 2, 3 and 4 are each 
responsible for 10% to 15% of cases [6]. Genotype 4 originates from African countries, and its 
rising prevalence in Western Europe appears to be fueled, at least in part, by the immigration of 
African persons to this region [6]. 
 
Pegylated interferon (PEG-IFN) alfa plus ribavirin combination therapy is the current gold 
standard treatment for chronic hepatitis C. In large multinational clinical trials, sustained 
virological response (SVR) is reported in 54% to 56% of patients, with rates higher (76%-82%) 
in genotype 2/3 patients and lower (42%-46%) in genotype 1 patients [7,8]. However, because of 
the stringent protocols used in these studies, including careful patient selection and regular clinic 
visits that promote motivation and adherence, it is unclear how closely these data reflect the 
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treatment of chronic hepatitis C in a community-based setting. General practice SVR rates are 
commonly thought to be lower than those attained in clinical trials, though clear evidence of this 
in the literature is sparse. 
 
We have, therefore, evaluated the treatment of Belgian patients with chronic hepatitis C receiving 
PEG-IFN alfa-2b (PegIntron; Schering-Plough, Kenilworth, NJ) and ribavirin administered 
according to a weight-based dosing schedule (Rebetol; Schering-Plough) in a community-based 
setting. 
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METHODS 
We conducted a community-based study of the treatment of chronic hepatitis C between January 
2003 and October 2004. The study protocol was approved by the ethics committee at each 
participating centre and in accordance with the principles set forth by the Declaration of Helsinki. 
 
Patients 
The study enrolled treatment-naive patients with chronic hepatitis C, as defined by detectable 
serum HCV RNA and elevated ALT levels (>1× upper limit of normal). All patients had to have 
genotype 1, 4 or 5 and were required to provide a liver biopsy specimen at baseline with a 
METAVIR score greater than 1. 
 
Exclusion criteria included decompensated liver cirrhosis or other chronic liver disease (hepatitis 
B, auto-immune hepatitis, haemochromatosis, alpha 1 antitrypsin deficiency, Wilson disease). 
Patients co-infected with HIV, with active alcohol abuse (defined as more than 30 g/day), or 
active intravenous drug abuse were also excluded. Finally, patients with ribavirin 
contraindications (chronic renal failure, anemia, haemoglobinopathy), leukocyte count less than 
3000 cells/µl and platelet count less than 100,000 cells/µl were excluded. 
 
Study design 
All patients received subcutaneous PEG-IFN alfa-2b (1.5µg/kg/wk) plus oral ribavirin (800-1200 
mg/day), according to body weight (patients weighing less than 65 kg received 800 mg/day, 
patients weighing between 65 and 85 kg received 1000 mg/day, patients heavier than 85 kg 
received 1200 mg/day) for 48 weeks. Patients were evaluated as outpatients for efficacy and 
tolerability on a monthly basis. 
 Page 7 of 28 
 
The primary end point of the study was SVR, defined as undetectable HCV RNA 6 months after 
the completion of treatment. End-of-treatment (EOT) response was defined as undetectable HCV 
RNA levels after 48 weeks of therapy. Non-responders were patients with detectable HCV RNA 
at all assessments during the treatment period, and virological breakthrough was defined as 
undetectable and subsequent reappearance of HCV RNA in a patient receiving therapy. 
 
The definition of early virological response (EVR) varied according to treatment center. 
Accordingly, two EVR definitions were used across the entire study cohort, as follows:  
1. ≥2 log10 reduction or undetectable HCV RNA at week 12 
2. Undetectable HCV RNA at week 24 
The dual definitions were the result of the differences in estimating EVR among the treating 
physicians. During the early part of this study, most physicians used qualitative PCR at week 24 
to assess EVR. Later, however, when data supporting the week 12 evaluation of EVR was 
published [9], the study procedure was amended to assess EVR at week 12, in line with evolving 
best practice. 
 
Qualitative HCV RNA levels were measured with use of Roche Amplicor  (Roche Molecular 
Systems, Pleasanton, OR, USA; lower limit of quantification [LLOQ] = 200 copies/ml). 
Quantitative HCV RNA was measured with use of Roche Monitor (Roche Molecular Systems; 
LLOQ = 2000 copies/ml)). HCV genotyping was performed with the use of InnoLipa 
(Innogenetics, Zwijaarde, Belgium). Serum ALT activity was determined using commercial 
reagents on an automated analyzer. Liver biopsy specimens were assessed by a local experienced 
pathologist who was unaware of the clinical and biochemical data. Histological results were 
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classified according the METAVIR system [10]. 
 
Statistical analyses 
Statistical analyses were performed on an intention-to-treat analysis. Parametric (Student t) and 
non-parametric (Mann–Whitney U) tests were used according to the distribution of the 
population. P < 0.05 was considered significant. 
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RESULTS 
Patient characteristics and disposition 
In total, 239 patients with chronic hepatitis C were screened by 64 physicians (gastroenterologists 
and hepatologists) at 46 centers in Belgium. Twenty patients were excluded: 4 patients did not 
start treatment, 1 was ineligible because HCV RNA was undetectable at the start of treatment, 5 
were infected with HCV genotype 2 or 3 after the study began and were subsequently removed, 
and 10 had METAVIR fibrosis scores of F0 or F1. The intention-to-treat-population, therefore, 
consisted of 219 patients who received at least 1 injection of PEG-IFN alfa-2b, 1 capsule of 
ribavirin, or both. 
 
Most patients had genotype 1 HCV, and 69% had a baseline viral load greater than 600,000 
IU/ml (Table 1). Twenty-two patients were of African origin, and all were infected with genotype 
4 HCV. All remaining patients were Caucasian. Twenty-three percent of patients had histories of 
drug abuse. 
 
In total, 121 of 219 patients completed 48 weeks of treatment, and 98 patients discontinued 
therapy early. Of the patients who did not complete the full treatment period, 41 did not attain 
EVR at week 12, 41 were discontinued because of poor tolerability, and 16 discontinued for other 
reasons. 
 
Sustained virological response 
In total, 108 of 219 (49.3%) patients had undetectable HCV RNA at the end of 48 weeks of 
therapy (Table 2, Figure 1). Of these, 18 (16.7%) patients had relapses with detectable HCV 
RNA during follow-up, and 91 (41.6%) attained SVR. Furthermore, 8 patients with SVR were 
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not assessed for HCV RNA at week 48; thus, the virological status of these patients at the end of 
treatment is unknown. One patient with detectable HCV RNA at the end of treatment had 
undetectable HCV RNA 24 months after treatment. 
 
Of the 111 patients who did not attain EOT response, 28 were non-responders with continuously 
detectable HCV RNA during the 48 week treatment period, 21 had virological breakthrough 
during treatment (i.e. reappearance of HCV RNA during therapy) and the remaining 62 had 
unknown virological status. Virology response data for genotype 1 and genotype 4 patients are 
also presented in Table 2. 
 
Early virological response 
EVR was assessed by 2 methods. In total, 199 subjects were assessed for EVR at week 12, week 
24, or both. Overall, 51 patients were assessed for EVR at week 12 only, 33 patients were 
assessed for EVR at week 24 only, and 115 patients were assessed for EVR at week 12 and week 
24 (Figure 2). Of the 148 (68%) patients assessed for HCV RNA status at week 24, 47 had 
detectable HCV RNA and 101 patients had undetectable HCV RNA.  
 
When considering week 12 and week 24 criteria, 134 of 219 patients were classified as having 
attained EVR; of those, 105 had EOT responses and 88 attained SVR (positive predictive value 
[PPV], 65.7%; Figure 3). In total, 87 of 88 patients with EVR who attained SVR had 
undetectable HCV RNA at the end of treatment. One patient who attained EVR but had 
detectable HCV RNA at the end of treatment also attained SVR (Figure 2). In contrast, 82 of 85 
patients who were not assessed or who did not attain EVR also did not attain SVR (negative 
predictive value [NPV], 96.5%; 70 were non-responders, and 12 experienced virological 
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breakthrough while on therapy). Of the 29 patients with EVR who did not attain EOT responses, 
9 had virological breakthroughs while on therapy, and 20 had unknown virological status. 
 
When considering week 12 EVR only, HCV RNA status was assessed in166 patients; of these, 53 
patients did not attain EVR. Thus, 113 of 166 patients attained week 12 EVR; of those, 65 
attained SVR. Thus, the PPV (proportion of EVR-positive patients who attained SVR) for the 
week 12 EVR assessment was 57%. Week 12 EVR was associated with an NPV of 92%. 
 
Predictors of response 
Age, fibrosis score and baseline viral load were identified as important predictors of treatment 
outcome (Table 3). In the overall study population and in the genotype 1 cohort, the mean age 
was significantly lower among patients who attained SVR than among those who did not (P < 
0.001). Baseline viral load and fibrosis score were also significant predictors of treatment 
outcome in the overall study population. 
 
The use of a weight-based ribavirin dosing regimen benefited patients throughout the entire 
weight spectrum, and there was no influence of body weight or body mass index (BMI) on SVR 
rates in the overall population or the genotype 1 cohort (Table 3). In genotype 4 patients, BMI 
and body weight were significantly associated with treatment outcome (P = 0.01); however, these 
data should be viewed with caution given the very low numbers of patients included in this 
analysis. 
 
Safety and tolerability 
Forty-one patients discontinued treatment early because of adverse events (n = 23) or serious 
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adverse events (n = 18). Ten patients discontinued treatment during weeks 1 to 12, 16 patients 
discontinued treatment during weeks 12 to 24, and the remaining 15 patients discontinued 
treatment after week 24. The most frequently reported serious adverse events resulting in 
treatment discontinuation were anemia (n = 11), fatigue/asthenia/malaise (n = 6) and fever (n = 
3). 
 
Adverse events were classified as hematological (anemia, n = 11; neutropenia, n = 2; 
pancytopenia, n = 2; thrombocytopenia, n = 3), general (n = 15), neuropsychiatric (n = 5), 
cutaneous (n = 5), optical neuropathic (n = 2) and gastrointestinal (n = 2).  
 
Six deaths occurred during the treatment period (median patient age, 61 years; intraquartile range, 
55-77 years). Causes of death were cardiovascular event (1 patient), sepsis (1 patient), 
hepatocellular carcinoma (1 patient), multiple organ failure after lung infection (1 patient), and 
unknown (2 patients). None of the deaths were considered related to the study except the 
cardiovascular event, which was considered by the investigator to be probably related to PEG-
IFN alfa-2b plus ribavirin treatment. 
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DISCUSSION 
Our data suggest that the SVR rates attained in large-scale clinical trials provide a realistic 
indication of the SVR rates achievable in a community-based setting. In our exclusively genotype 
1 and genotype 4 population, SVR rates were remarkably akin to those reported for similar 
cohorts in large clinical trials (42% vs 42%-52% [7,8,11]). Interestingly, the final results of a 
large Canadian community-based study (POWeR), which incorporated a weight-based ribavirin 
administration schedule (800-1200 mg/day according to body weight) in combination with PEG-
IFN alfa-2b, also supports a close relationship between SVR rates in clinical trials and those 
attained in a community-based setting [12]. SVR rates were similar in genotype 1 patients in 
POWeR and in the present study (42% vs 40%). Furthermore, the findings of AWB, a 
community-based surveillance study that also made use of weight-based ribavirin dosing (800-
1200 mg/day according to body weight) with PEG-IFN alfa-2b (1.5 µg/kg/wk) in Germany, 
support the use of a weight-based ribavirin regimen [13]. A recent interim analysis of this study 
reported highly favorable SVR rates of 66% in a predominantly genotype 1, 4, 5, 6 population. 
Collectively, these data are encouraging and may help to dispel the perception that SVR rates 
reported in large clinical trials are generally not attainable in routine clinical practice. 
 
Weight-based ribavirin dosing appears to be a critical factor in the success of community-based 
studies such as POWeR and AWB and also in the present study. The benefits associated with 
weight-based dosing of ribavirin were first suggested by Manns et al. [8]. Logistic regression 
analysis of data from patients receiving PEG-IFN alfa-2b plus ribavirin at a fixed dose of 800 
mg/day indicated that baseline body weight is an important predictor of SVR. These authors 
found that an increasing ribavirin dose per unit body weight was positively correlated with SVR 
to a threshold of approximately 13 mg/kg/day, after which further increases in ribavirin dose 
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were not paralleled by increasing SVR rates [8]. Manns et al. [8] conclude that a ribavirin dose 
range of between 11 and 15 mg/kg/day provides an effective balance between safety and efficacy. 
More recently, the merits of weight-based ribavirin dosing have received further affirmation from 
the results of the WIN-R study, which incorporated a structured, weight-based ribavirin schedule 
plus PEG-IFN alfa-2b into a large community-based prospective clinical trial [14]. In genotype 1 
patients, SVR rates were significantly higher among those receiving weight-based ribavirin (800-
1400 mg/day) than in those receiving a fixed 800 mg/day dose (34% vs 29%; P = 0.004). Weight-
based dosing of ribavirin was approved in 2001 by the European Medicines Evaluation Agency, 
encouraging the wider adoption of this regimen into routine clinical practice. In our study, the 
absence of body weight or BMI as a predictor of treatment outcome, coupled with SVR rates that 
are comparable to previous clinical trial data, suggests that weight-based ribavirin dosing is an 
effective treatment approach in the community setting. 
 
Age, baseline viral load, and fibrosis score were identified as significant predictors of treatment 
outcome. Again, these observations closely parallel previous clinical trial data that have also 
identified these characteristics as related to treatment outcome [7,8,11,15]. Zeuzem [15] 
suggested that because these factors are independently associated with treatment outcome, they 
have a cumulative effect on treatment outcomes when they exist in tandem. The least favorable 
population from the perspective of treatment outcomes would include genotype 1, 4, 5 or 6 HCV, 
high baseline viral load, age >40 years, male gender, and septal fibrosis or cirrhosis [15,16]. In 
this context, our overall SVR rate of 42% is particularly impressive. Eighty-three percent of 
patients in the present study had genotype 1 HCV, 69% had baseline viral load greater than 
600,000 IU/ml, more than 75% were older than 40 years, 54% were male, and more than 40% 
had bridging fibrosis or cirrhosis. Similar demographics were also reported for the POWeR study 
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cohort (approximately 60% genotype 1, 52% with viral load >600,000 IU/ml, 40% with bridging 
fibrosis or cirrhosis [12]) possibly indicating that these difficult-to-treat patients are more 
frequently encountered in routine clinical practice and are generally under-represented in clinical 
trials. 
 
Treatment discontinuation may also be more prevalent in the community-based management of 
chronic hepatitis C than in large-scale clinical trials in which patients can benefit from frequent 
physician visits and motivational support. In total, 18% of patients in the present study 
discontinued therapy because of poor tolerability, similar to rates reported in clinical trials (14%-
22% [7,8,11]). Again, these data contradict the popular theory that patients in general clinical 
practice do not receive the same level of motivational support patients enrolled in clinical trials 
receive, and this translates to lower adherence and higher dropout rates in community-based 
settings. 
 
The predictive value of EVR in this study is difficult to determine because of the change in 
practice that occurred during the conduct of the study. Once it was realized that week 12 
evaluation of HCV RNA levels provided an accurate prediction of treatment outcome, we 
modified our approach to accommodate this important treatment advance; unfortunately, this 
change also confounded the analysis of our data. Nevertheless, some basic conclusions can be 
drawn from our data. In total, 92% of patients who did not attain an EVR at week 12 also did not 
attain SVR. Our subanalysis of only those patients with HCV RNA levels assessed at week 12 is, 
therefore, consistent with previously reported data highlighting the very high NPV of this 
assessment and validating its use as an early stopping rule. This reinforces the strategies of 
assessing EVR at week 12 and of withdrawing from treatment patients who have detectable HCV 
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RNA at week 24. Both approaches are now regarded as integral elements of the individualized 
approach to the treatment of patients with chronic hepatitis C [17]. 
 
In conclusion, our data indicate that PEG-IFN alfa-2b plus weight-based ribavirin therapy for 
chronic hepatitis C resulted in favorable treatment outcomes in general clinical practice in a 
Belgian cohort. Further community-based studies of therapy for chronic hepatitis C are required 
to distinguish the differences and similarities in findings between clinical trials and routine 
practice and to help provide relevant, evidence-based treatment regimens within a community-
based setting. 
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Table 1 Patient demographics 
 
Variables 
Total study population 
(N = 219) 
Age, years (range) 51 (41–61) 
Male, % 54 
Weight, kg (range) 72 (63–82) 
Body mass index, kg/m² (range) 25 (21–28) 
Genotype, n (%) 
 1 
 4 
 5 
 Unknown 
 
181 (83) 
31 (15) 
5 (2) 
1 (<1) 
Viral load, n (%)  
 >600,000 IU/ml 
 ≤600,000 IU/ml 
 
151 (69) 
68 (31) 
Percentage of fibrosis, n (%) 
 F2 
 F3 
 F4 
 Unknown 
 
118 (54.0) 
45 (20.5) 
45 (20.5) 
11 (5.0) 
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Table 2 Virological responses 
 
 All patients 
(N = 219) 
Genotype 1 
(n = 181) 
Genotype 4 
(n = 31) 
 
Early virological response, n (%) 
 
134 (61.2) 
 
112 (61.1) 
 
17 (54.8) 
End-of-treatment response, n (%) 108a (49.3) 88 (48.6) 16 (51.6) 
Relapse, n (%) 18 (16.7) 16 (18.2) 2 (12.5) 
Sustained virological response, n (%) 91b (41.6) 73 (40.3) 14 (45.2) 
a Of these 108 patients, 105 patients attained early virological response but 3 patients did not. 
b One patient had detectable HCV RNA at week 48 but undetectable HCV RNA 24 weeks after 
treatment; 8 patients were not assessed at week 48 but attained sustained virological response. 
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Table 3 Predictors for sustained virological response in the entire population and in genotype 1 and genotype 4 cohorts 
 
 All patients (N = 219)  Genotype 1 (n = 181)  Genotype 4 (n = 31) 
 SVR 
(n = 91) 
No SVR    (n 
= 128) 
P  SVR 
(n = 72) 
No SVR  (n 
= 109) 
P  SVR 
(n = 14) 
No SVR 
(n = 17) 
P 
Age, y (rangea) 46 (35-58) 54 (44-64) <0.001  47 (36-58) 55 (45-64) <0.001  37 (30-47) 49 (43-58) < .01 
Gender (n) 
 Male 
 Female 
 
46 
45 
 
73 
55 
 
0.38 
  
36 
36 
 
62 
47 
 
0.45 
  
9 
5 
 
10 
7 
 
0.9 
 
Weight, kg (range1) 71.4 
(62.5–81.0) 
72.5 
(64.0–82.0) 
0.42  71  
(62–80) 
72  
(63–82) 
0.8  71 
(67–82) 
81 
(73–92) 
0.01 
BMI, kg/m2 (range1) 24.6 
(21.6–27.94) 
25.2 
(22.8–28.4) 
0.26  24.7  
(21.7–28.0) 
24.9  
(22.6–27.7) 
0.74  23.4 
(20.5–25.8) 
27.3 
(24.7–34.1) 
0.01 
Fibrosis, n (%) 
 F2 
 F3-F4 
 
66 (77) 
20 (23) 
 
52 (43) 
69 (57) 
 
<0.001 
  
49 (72) 
19 (28) 
 
42 (41) 
61 (59) 
 
<0.01 
  
12 (92) 
1 (8) 
 
10 (59) 
7 (41) 
 
0.1 
Viral load, n (%) 
 >600,000 IU/ml 
 ≤600,000 IU/ml 
 
46 (51) 
33 (36) 
 
85 (59) 
27 (21) 
 
0.01 
  
39 (54) 
24 (33) 
 
73 (67) 
19 (17) 
 
0.08 
  
5 (36) 
8 (57) 
 
10 (59) 
4 (24) 
 
0.18 
 
SVR, sustained virological response. 
a Intraquartile, representing range between 25th and 75th quartiles. 
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Fig. 1. Treatment outcomes. EOT, end-of-treatment response; EVR, early virological response; G1, genotype 1; G4, genotype 4; NR, 
non-response; SVR, sustained virological response.. 
 
Fig. 2 Assessment of early virological response. Patients with breakthrough viremia had undetectable HCV RNA at week 12 of therapy 
but detectable HCV RNA later during therapy. * Three patients who did not attain EVR attained EOT response and SVR. EVR, early 
virological response; PEG-IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virological response; EOT, end of treatment.  
 
Fig. 3 Early virological response as predictor of treatment outcome. (A) All patients, weeks 12 and 24 EVR criteria. (B) Week 12 EVR 
subanalysis. EVR, early virological response; HCV, hepatitis C virus; PPV, positive predictive value; NPV, negative predictive value. 
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Fig. 1. Treatment outcomes. EOT, end-of-treatment response; EVR, early virological response; G1, genotype 1; G4, genotype 4;  SVR, 
sustained virological response. 
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Fig. 2 Assessment of early virological response. Patients with breakthrough viremia had undetectable HCV RNA at week 12 of therapy 
but detectable HCV RNA later during therapy. * Three patients who did not attain EVR attained EOT response and SVR. EVR, early 
virological response; PEG-IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virological response; EOT, end of treatment.  
Chronic hepatitis C patients 
receiving PEG-IFN alfa-2b plus RBV
N=219
51 patients assessed 
for EVR at week 12
EVR: n = 33
No EVR: n = 18
134 patients attained EVR 53 patients failed to attain EVR
33 patients assessed 
for EVR at week 24
EVR: n = 26
No EVR: n = 7
115 patients assessed for 
EVR at weeks 12 and 24
EVR n = 75
No EVR n = 28
Breakthrough: n = 12
Undetectable HCV RNA 
at week 48 (n=105)
•SVR = 87
•Relapse = 18
Detectable HCV RNA at 
week 48 (n=29)
•Not done ** = 20
•Breakthrough = 9
•(SVR =1)
EOT: n = 3
SVR *: n = 3
20 patients were not 
assessed for EVR
 
 
** 6 months follow -up
 Page 26 of 28 
Fig. 3 Early virological response as predictor of treatment outcome. (A) All patients, weeks 
12 and 24 EVR criteria. (B) Week 12 EVR subanalysis. EVR, early virological response; 
HCV, hepatitis C virus; PPV, positive predictive value; NPV, negative predictive value. 
A                
≥2log reduction or 
undetectable HCV 
RNA at week 12 or
Undetectable HCV 
RNA at week 24
N=219
85 / 219
38.8%
82 / 85
(NPV = 96.5%)
3 / 85
(3.5 %)
134 / 219
61.2%
46 / 134
(35.5%)
88 / 134
(PPV = 65.7%)
Yes
No
Yes
Yes
No
No
 
B           
≥2log reduction 
or undetectable 
HCV RNA at 
week 12 
(n=166)
52 / 166
31.3%
48 / 52
(NPV = 92%)
4 / 52
(8%)
114 / 166
68.7%
49 / 114
(43%)
65 / 114
(PPV = 57%)Yes
No
Yes
Yes
No
No
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Appendix 1. List of participating centres 
Investigator Site 
Dr. Assene Collins Hôp Ixelles (Iris sud) 
Dr. Bastens Clin. St.-Joseph 
Dr. Bataille CH Hutois 
Dr. Bekhti Centre Médical de Chéri 
Dr. Boon CHU Erasme 
Dr. Botembe CH de l'Ardenne 
Dr. Bourgeois N. CHU Erasme 
Dr. Braxel Privé - Eedverbondkaai 
Dr. Brenard Hôpital St.-Joseph 
Dr. Brixko  CHR de la Citadelle 
Dr. Cabooter AZ St-Jan 
Dr. Castelain Clin. des 2 Alice 
Dr. Coche Clin. St.-Pierre 
Dr. Colin Clin. Europe St-Michel - Bruxelles 
Dr. De Galocsy Clin. St. Anne / St. Rémi 
Dr. De Koninck Clin. St.-Pierre 
Dr. De Maeyer AZ St Elisabeth Herentals 
Dr. Delwaide - Liège CHU Sart Tilman 
Dr. Delwaide - Verviers CHR La Tourelle 
Dr. Denié CHU Hornu 
Dr. Dewyspelaere Stedelijk Ziekenhuis Roeselare 
Dr. D'Harveng CHU Mouscron 
Dr. D'heygere AZ Groeninghe Kortrijk 
Dr. Fiasse Clin. des 2 Alice 
Dr. Floriani CH Hutois 
Dr. Francque UZ Antwerpen 
Dr. Gehenot St-Elisabeth Namur 
Dr. Hittelet ULB Erasme 
Dr. Holvoet AZ Campus Middelheim 
Dr. Hulstaert AZ Jan Portaels (b.v.b.a. Gastric) 
Dr. Harlet H. Hart ZH - Campus Menen 
Dr. Lanmbrecht AZ Damiaan Oostende 
Dr. Lammens Clin. Générale St.-Jean 
Dr. Langlet CHU Brugmann 
Dr. Lasser CHU Brugmann 
Dr. Laukens AZ St-Jan 
Dr. Lefèbvre CHR Namur 
Dr. Moulart CH Hornu-Frameries 
Dr. Mulkay CHU St. Pierre 
Dr. Mullier CHU Joseph Bracops  
Dr. Nakad Clin. Notre Dame 
Dr. Nicholas Clin. Notre Dame 
Dr. Orlent AZ St-Jan 
Dr. Paul Clin. Europe St-Michel - Bruxelles 
Dr. Ponette St-Marie ZH Halle 
Dr. Reynaert AZ VUB 
Dr. Robaeys ZOL Genk 
Dr. S. Bourgeois AZ Stuivenberg 
Dr. Sermon AZ VUB 
Dr. Solbreux Clin. St.-Joseph 
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Dr. Sprengers St. Augustinus 
Dr. Thys CH Bois de l'Abbaye 
Dr. Van Vaerenbergh H. Hart 
Prof.Dr. Van Vlierberghe UZ Gent 
Dr. Wain CHR La Tourelle 
Dr. Warzee CHNDRF 
Prof Adler CHU Erasme 
Prof Henrion Hôpital de Jolimont 
Prof Horsmans UCL St.-Luc 
Prof Michielsen UZ Antwerpen 
Prof Nevens UZ Gasthuisberg Leuven 
Prof Van Steenbergen UZ Gasthuisberg Leuven 
Prof Yap UZ Gasthuisberg Leuven 
Prof. Colle UZ Gent 
 
 
